Alliance Foundation Trials And Natera Announce Aft-70 Navigate A Global, Randomized, Phase Iii Trial Evaluating Genentech’S Oral Selective Estrogen Receptor Degrader With Signatera Mrd-Guided Cdk4/6 Inhibitor Therapy In Breast Cancer

By Reuters News

- Natera, Inc. NTRA.O:

  • ALLIANCE FOUNDATION TRIALS AND NATERA ANNOUNCE AFT-70 NAVIGATE: A GLOBAL, RANDOMIZED, PHASE III TRIAL EVALUATING GENENTECH’S ORAL SELECTIVE ESTROGEN RECEPTOR DEGRADER (SERD) WITH SIGNATERA™ MRD-GUIDED CDK4/6 INHIBITOR THERAPY IN BREAST CANCER

Further company coverage: NTRA.O

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk